Here are our responses to the September, 2020 Quick Question, wich attracted 51 participants.
How does your facility measure fibrinolysis?
- Plasminogen: 3 [5%]
- Tissue plasminogen activator [TPA]: 1 [2%]
- Plasminogen activator inhibitor 1 [PAI-1]: 1 [2%]
- Thromboelastograph [TEG]: 10 [20%]
- Rotational thromboelastometry [ROTEM]: 36 [71%]
As we speculated the first three measures of fibrinolysis are rarely performed, and are mostly accesible from specialty reference laboratories, perhaps because they require special specimen management to prevent post-collection in vivo fibrinolysis, especially TPA. The TEG and ROTEM offer global near-patient assays that report fibrinolysis as the LY-30 [TEG] or the ML. Both measures are seen to report hypofibrinolysis in SARS-CoV-2 infection. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost doi: 10.1111/JTH.14850
The percentage of ROTEM versus TEG selections may reflect the demographics of our participants, as the ROTEM is prevalent in Europe while the TEG is popuar in North America.
No comments here.